Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study - SUPPLEMENTAL MATERIAL
Published: 11 April 2023| Version 1 | DOI: 10.17632/tpgy3dwkf5.1
Contributor:
Description
Supplemental data for publication: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study
Files
Institutions
University of Arizona
Categories
Publication